Business · 06/02/2026Updated: 10/16/2026 · 1 min read
Determination of Regulatory Review Period for Purposes of Patent Extension; AURORA EV-ICD
Summary
The FDA has determined the regulatory review period for AURORA EV-ICD, a medical device, due to patent extension applications submitted to the USPTO.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →